A Comparison of Fulvestrant Plus a Targeted Agent With Fulvestrant Alone in Hormone Receptor-Positive Advanced Breast Cancer That Progressed on Prior Endocrine Therapy: A Meta-Analysis

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s166653
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Cost Effectiveness of Fulvestrant 500 Mg in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer in the UK

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Fulvestrant ('Faslodex')--A New Treatment Option for Patients Progressing on Prior Endocrine Therapy

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2002English

A Randomized Trial of Combination Anastrozole Plus Gefitinib and of Combination Fulvestrant Plus Gefitinib in the Treatment of Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer

Breast Cancer Research and Treatment
Cancer ResearchOncology
2012English

Pcn171 - A Cost-Utility Analysis of Fulvestrant Versus Anastrozole as First-Line Therapy for Oestrogen Receptor-Positive Locally Advanced and Metastatic Breast Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Fulvestrant Treatment Is Associated With Cholesterol Plasma Level Reduction in Hormone Receptor-Positive Metastatic Breast Cancer Patients

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2009English

Predictors of Prolonged Benefit From Palbociclib Plus Fulvestrant in Women With Endocrine-Resistant Hormone Receptor–positive/Human Epidermal Growth Factor Receptor 2–negative Metastatic Breast Cancer in PALOMA-3

European Journal of Cancer
Cancer ResearchOncology
2018English

Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2014English

Review of Hormone-Based Treatments in Postmenopausal Patients With Advanced Breast Cancer Focusing on Aromatase Inhibitors and Fulvestrant

ESMO Open
Cancer ResearchOncology
2016English

Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy